Aging Populations And Targeted Oncology Will Expand Markets Despite Risks
AN
AnalystHighTarget
Not Invested
Consensus Narrative from 2 Analysts
Published
29 May 25
Updated
23 Jul 25
AnalystHighTarget's Fair Value
US$4.00
23.3% undervalued intrinsic discount23 Jul
US$3.07
1Y
-14.5%7D
-8.1%